Skip to main content

Table 3 BiTes currently in trials

From: Emerging therapies in mantle cell lymphoma

BiTe NCT#/publication Route/administration schedule Phase Sample size* [follow-up**] Median lines of prior therapy ORR% [CR%] CRS [grade ≥ 3] Neurotoxicity [grade ≥ 3]
Blinatumomab NCT00274742 [95, 96] IV continuous infusion over 4 or 8 weeks I 24 [5.2] 3 71.1a [42.8] NP [NP] 71 [22]
Mosunetuzumab NCT02500407 [97] IV once every 21 days I/Ib 23 [NP] 3 NP [NP] 28.9 [1.4] 43.7 [3.2]
REGN1979 NCT03888105 [98] IV weekly for 12 weeks, then every 2 weeks for 24 weeks I 6 [NP] 3 NP [NP] 57 [7.2] NP [3.1]
GEN3013 NCT03625037 [99] Subcutaneous weekly: cycle 1–2; every 2 weeks cycle 3-6; every 28 days thereafter I/II NP 3 NP [NP] 50 [0] 0 [0]
  1. Abbreviations: NR not reached, NP not presented, ORR overall response rate, CR complete response, PFS progression-free survival, CRS cytokine release syndrome
  2. aResponse rate at the target dose of ≥ 60 ug/m2/day (n = 7 MCL patients)
  3. *The sample size denotes only MCL patients
  4. **f/up in months